Alprostadil - Pfizer

Drug Profile

Alprostadil - Pfizer

Alternative Names: Caverject; Prostaglandin E1 - Pfizer

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Erectile dysfunction

Most Recent Events

  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 13 Jul 2001 A study has been added to the adverse events and Men's Health therapeutic trials sections
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top